Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Chia

Showing results (271-280 of 280) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 280 results.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
Journal of the National Cancer Institute|December 10, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trialYara Abdou, William E Barlow, Julie R Gralow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trialS Delaloge, D Cella, Y Ye, et al.
The Lancet. Oncology|February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialArlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
Cancer|September 23, 2025
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFTKarin Ribi, Bernard F Cole, Gini F Fleming, et al.
The Lancet. Oncology|November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
The New England Journal of Medicine|December 16, 2021
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast CancerKevin Kalinsky, William E Barlow, Julie R Gralow, et al.
ESMO Open|September 17, 2024
Phase I PIANO trial-PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomesR Sundar, D K A Chia, J J Zhao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 2, 2026
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancerP A Francis, O Pagani, G F Fleming, et al.
International Journal of Surgery (London, England)|October 1, 2021
Medical student engagement with surgery and research during the COVID-19 pandemic: Supporting the future workforce for post-pandemic surgical recoveryShiraz Q Shafi, Samuel Brown, Rachel A Khaw, et al.
Pageof 28

Showing results (271-280 of 280) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 280 results.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
Journal of the National Cancer Institute|December 10, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trialYara Abdou, William E Barlow, Julie R Gralow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trialS Delaloge, D Cella, Y Ye, et al.
The Lancet. Oncology|February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialArlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
Cancer|September 23, 2025
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFTKarin Ribi, Bernard F Cole, Gini F Fleming, et al.
The Lancet. Oncology|November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
The New England Journal of Medicine|December 16, 2021
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast CancerKevin Kalinsky, William E Barlow, Julie R Gralow, et al.
ESMO Open|September 17, 2024
Phase I PIANO trial-PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomesR Sundar, D K A Chia, J J Zhao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 2, 2026
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancerP A Francis, O Pagani, G F Fleming, et al.
International Journal of Surgery (London, England)|October 1, 2021
Medical student engagement with surgery and research during the COVID-19 pandemic: Supporting the future workforce for post-pandemic surgical recoveryShiraz Q Shafi, Samuel Brown, Rachel A Khaw, et al.
Pageof 28